Eli Lilly has quietly provided its investigational weight-loss drug retatrutide to just one person under a compassionate use program. The disclosure was made in a STAT News report that highlighted the narrow scope of access to the so-called triple-G therapy.
Retatrutide, which targets three gut hormone receptors, is among a new class of highly anticipated obesity treatments still in clinical trials. The drug's developer has not publicly detailed why this specific patient qualified or how the decision was made.